Loading…
Kiniksa Pharmaceuticals International, plc is projected to rise to $110.01 by 2027, a +41% move from its current price of $78.20. KNSA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $76.10 | $78.24 | $80.44 | +0.05% |
| Aug 2 | $75.26 | $78.27 | $81.40 | +0.09% |
| Aug 3 | $74.64 | $78.31 | $82.16 | +0.14% |
| Aug 4 | $74.12 | $78.35 | $82.81 | +0.19% |
| Aug 5 | $73.67 | $78.38 | $83.40 | +0.23% |
| Aug 6 | $73.27 | $78.42 | $83.93 | +0.28% |
| Aug 7 | $72.91 | $78.46 | $84.43 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $72.91 | $78.46 | $84.43 | +0.33% |
| Week 2 | $70.96 | $78.71 | $87.32 | +0.66% |
| Week 3 | $69.55 | $78.97 | $89.67 | +0.99% |
| Week 4 | $68.42 | $79.23 | $91.75 | +1.32% |
| Week 5 | $67.46 | $79.49 | $93.66 | +1.65% |
| Week 6 | $66.63 | $79.75 | $95.45 | +1.98% |
| Week 7 | $65.90 | $80.01 | $97.16 | +2.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company that develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Kiniksa Pharmaceuticals International, plc trades under the symbol KNSA. The stock is currently priced at $79.44 per share, with a market capitalization of $6.11B and a market rank of 1186. These figures reflect its current market standing and positioning within the healthcare sector.
A major floor 45.7% below — a decisive break under it would weaken the trend.
The nearest floor, 30.7% below — buyers have tended to step in here.
The nearest ceiling, 3.5% above — a clean break opens room to run.
A major ceiling 25.1% above — clearing it would confirm fresh momentum.
Key KNSA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KNSA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $72.99 | Buy | $74.51 | Buy |
| MA 10 | $68.05 | Buy | $70.37 | Buy |
| MA 20 | $65.72 | Buy | $66.45 | Buy |
| MA 50 | $58.38 | Buy | $60.65 | Buy |
| MA 100 | $53.79 | Buy | $55.47 | Buy |
| MA 200 | $47.79 | Buy | $48.98 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 72.47 | Sell |
| Stoch RSI (14) | 73.46 | Neutral |
| CCI (20) | 193.62 | Buy |
| Williams %R (14) | -13.61 | Info |
| MACD (12,26,9) | 1.52 | Buy |
| ROC (12) | 26.17 | Buy |
| Bollinger %B (20,2) | 1.02 | Sell |
| Stochastic %K (14) | 86.39 | Sell |
| TRIX (15) | 0.70 | Buy |
| Awesome (5,34) | 10.84 | Buy |
| Ultimate (7,14,28) | 77.67 | Sell |
| Momentum (10) | 17.09 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 81.01 | Sell |
| ADX (14) | 26.98 | Buy |
| ATR (14) | 2.32 | Info |
The near-term technical picture is bullish with a 14-day RSI of 60. The stock trades above both the SMA50 of $56.91 and the SMA200 of $47.04, suggesting upside potential. Support is at $51.58 and resistance at $67.29, with the 30-day range spanning from $68.34 to $92.34. Annualized volatility stands at 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $37.92 | $78.20 | $109.14 | 0% | Neutral | |
| $87.60 | $110.01 | $146.13 | +41% | Bullish | |
| $116.81 | $150.96 | $208.32 | +93% | Bullish | |
| $132.59 | $175.48 | $249.42 | +124% | Bullish | |
| $148.81 | $201.10 | $293.03 | +157% | Bullish | |
| $163.92 | $225.77 | $336.18 | +189% | Bullish | |
| $166.20 | $233.00 | $353.73 | +198% | Bullish | |
| $198.26 | $282.59 | $436.61 | +261% | Bullish | |
| $233.19 | $337.67 | $530.18 | +332% | Bullish | |
| $260.36 | $382.75 | $610.01 | +389% | Bullish | |
| $361.97 | $569.86 | $966.88 | +629% | Bullish | |
| $843.61 | $1,494.54 | $2,777.43 | +18.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $37.92 | $78.20 | $91.23 | +0.00% |
| August 2026 | $66.84 | $78.47 | $94.29 | +0.35% |
| September 2026 | $68.93 | $81.61 | $99.41 | +4.00% |
| October 2026 | $72.62 | $86.57 | $106.59 | +6.08% |
| November 2026 | $72.96 | $87.47 | $108.63 | +1.04% |
| December 2026 | $72.36 | $87.20 | $109.14 | -0.31% |
Click any year to see its month-by-month KNSA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, KNSA could reach as high as $109.14, with a base case around $78.20 and support toward $37.92 — roughly 0% from $78.20. Price action looks broadly range-bound.
Expect KNSA to range from $87.60 to $146.13 through 2027. The $110.01 average target implies a +41% move from current prices. That is up +41% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The KNSA price prediction for 2028 points to an average of $150.96 (low $116.81, high $208.32) — a potential gain of +93% on today's $78.20. Momentum favours further upside here.
In 2029, KNSA is projected to trade between $132.59 and $249.42, averaging $175.48 — a potential gain of +124% from today's $78.20. That is up +16% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Kiniksa Pharmaceuticals International, plc's 2030 outlook centres on $201.10, within a $148.81 to $293.03 range. That is up +15% on the projected 2029 average. That marks a +157% change versus current levels. Momentum favours further upside here.
By 2031, KNSA could reach as high as $336.18, with a base case around $225.77 and support toward $163.92 — roughly +189% from $78.20. Buyers look set to stay in control over this stretch.
Expect KNSA to range from $166.20 to $353.73 through 2032. The $233.00 average target implies a +198% move from current prices. That is up +3% on the projected 2031 average. Momentum favours further upside here.
The KNSA price prediction for 2033 points to an average of $282.59 (low $198.26, high $436.61) — a potential gain of +261% on today's $78.20. Buyers look set to stay in control over this stretch.
In 2034, KNSA is projected to trade between $233.19 and $530.18, averaging $337.67 — a potential gain of +332% from today's $78.20. That is up +19% on the projected 2033 average. Momentum favours further upside here.
Kiniksa Pharmaceuticals International, plc's 2035 outlook centres on $382.75, within a $260.36 to $610.01 range. That is up +13% on the projected 2034 average. That marks a +389% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, KNSA could reach as high as $966.88, with a base case around $569.86 and support toward $361.97 — roughly +629% from $78.20. Momentum favours further upside here.
Expect KNSA to range from $843.61 to $2,777.43 through 2050. The $1,494.54 average target implies a +18.1x move from current prices. That is up +162% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in KNSA today (≈ 12.787724 KNSA) could be worth
$19,111.82
+$18,111.82 (+1811%) by 2050 · US Dollar
Based on the average projected KNSA price of $1,494.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KNSAwould be worth at today's price.
$1,000 invested in KNSA on Jul 30, 2025 (≈ 33.2668 KNSA) would be worth
$2,601.46
+$1,601.46 (+160.1%) today · 2.60× · US Dollar
Based on a KNSA entry price of $30.06 vs. today's $78.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $63.05 | $1,240.29 | +24.0% |
| 1 month ago | $63.95 | $1,222.83 | +22.3% |
| 3 months ago | $55.27 | $1,414.87 | +41.5% |
| 6 months ago | $43.92 | $1,780.51 | +78.1% |
| 1 year ago | $30.06 | $2,601.46 | +160.1% |
| All time (5.0y) ago | $16.23 | $4,818.24 | +381.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KNSA forecast.
Our base-case forecast reaches $160.00 around 2029.
Implied market cap at $160.00: $7.41B
The multi-year forecast shows a clear bullish trajectory across several years. For 2026, the min, avg, and max are $37.92, $79.44, and $108.03 respectively, with an ROI of 0 and a NEUTRAL sentiment. By 2027 the forecast expands to an avg of $107.10 and a max of $139.12, with ROI of 34.8 and a BULLISH sentiment.
In 2028 the avg rises to $141.16 (min $111.61, max $189.33) with ROI 77.7 and BULLISH sentiment, and 2029 shows an avg of $162.87 (min $126.35, max $224.01) with ROI 105. By 2030, the avg is $184.81 (min $140.99, max $259.61) with ROI 132.6 and BULLISH sentiment. The forecast continues to rise in subsequent years, with 2031 at avg $205.60, 2032 at $214.50, 2033 at $253.81, 2034 at $295.43, 2035 at $332.72, 2040 at $490.34, and 2050 at $1,209.81 as the avg, with max values reaching as high as $2,098.96 and ROI of 1422.9.
These projections reflect a sustained bullish outlook but remain estimates, not guarantees, and are subject to market and clinical development risks.
Tap a question to reveal the answer.
For 2030, the forecast shows an avg price of $184.81, with a min of $140.99 and a max of $259.61, and a ROI of 132.6, with a BULLISH sentiment.
The forecast indicates a bullish trajectory from 2027 onward, with rising averages (2027 avg $107.10; 2028 $141.16; 2029 $162.87; 2030 $184.81; 2031 $205.60; 2032 $214.50; 2033 $253.81; 2034 $295.43; 2035 $332.72; 2040 $490.34; 2050 $1,209.81) and increasing ROI values, though 2026 is listed as Neutral with an avg of $79.44. These are estimates and not guarantees.
The 2050 forecast shows a max of $2,098.96, with an avg of $1,209.81 and a min of $748.22, so a peak above $2,000 is within the stated max forecast but not guaranteed.
The current price is $79.44 per share and the market capitalization is $6.11B.
The near-term picture is bullish with RSI at 60. The stock is above the SMA50 of $56.91 and the SMA200 of $47.04, with support at $51.58 and resistance at $67.29. The 30-day range is $68.34 to $92.34, and annualized volatility is 40%.
Kiniksa Pharmaceuticals International, plc Community Discussion
0Share your Kiniksa Pharmaceuticals International, plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.